Patrys Ltd
ASX:PAB
Patrys Ltd
Cash & Cash Equivalents
Patrys Ltd
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Patrys Ltd
ASX:PAB
|
Cash & Cash Equivalents
AU$4.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-8%
|
|
Immutep Ltd
ASX:IMM
|
Cash & Cash Equivalents
AU$103.7m
|
CAGR 3-Years
24%
|
CAGR 5-Years
32%
|
CAGR 10-Years
20%
|
|
Mesoblast Ltd
ASX:MSB
|
Cash & Cash Equivalents
$77.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Cash & Cash Equivalents
$1B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash & Cash Equivalents
AU$38.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash & Cash Equivalents
AU$123.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
See Also
What is Patrys Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.5m
AUD
Based on the financial report for Dec 31, 2023, Patrys Ltd's Cash & Cash Equivalents amounts to 4.5m AUD.
What is Patrys Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-8%
Over the last year, the Cash & Cash Equivalents growth was 16%. The average annual Cash & Cash Equivalents growth rates for Patrys Ltd have been -30% over the past three years , -6% over the past five years , and -8% over the past ten years .